论文部分内容阅读
目的观察川芎嗪联合血栓通治疗缺血性脑卒中的临床效果。方法将2015年3月-2017年7月收治的缺血性脑卒中患者300例按照随机数字表法分为A组和B组各150例,A组给予血栓通治疗,B组给予川芎嗪联合血栓通治疗,对比2组临床疗效。结果 2组患者治疗前神经功能缺损评分比较差异无统计学意义(P>0.05),治疗后2组患者神经功能缺损评分均降低,且B组明显低于A组,差异均有统计学意义(P<0.05)。A组总有效率为81.3%低于B组的90.0%,差异有统计学意义(χ2=5.473,P<0.05)。结论川芎嗪联合血栓通治疗缺血性脑卒中的临床效果显著,值得临床推广应用。
Objective To observe the clinical effect of ligustrazine combined with Xueshuantong in treating ischemic stroke. Methods 300 patients with ischemic stroke admitted from March 2015 to July 2017 were divided into 150 cases in group A and group B according to the random number table. Group A was treated with Xueshuantong and group B was given ligustrazine Xueshuantong treatment, compared the clinical efficacy of two groups. Results There was no significant difference in scores of neurological deficits between the two groups before treatment (P> 0.05). After treatment, the scores of neurological deficit decreased in both groups, and the scores in group B were significantly lower than those in group A (P <0.05) P <0.05). The total effective rate in group A was 81.3%, which was lower than that in group B 90.0% (χ2 = 5.473, P <0.05). Conclusion The clinical effect of ligustrazine and Xueshuantong in treating ischemic stroke is significant and worthy of clinical application.